• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ALA

AROVELLA THERAPEUTICS LIMITED - Corporate Spotlight

1.02% ! 9.9¢
Market Cap $116.4M  !
Healthcare Biotechnology
Add to My Watchlist

Arovella Therapeutics Limited is a biotechnology company. The Company is focused on... Arovella Therapeutics Limited is a biotechnology company. The Company is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. The Company's lead product is ALA-101. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. ALA-101 is a next-generation CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukemias. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. The Company is also engaged in expanding solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Its iNKT cells also contain an invariant T cell receptor (iTCR) that targets alpha-galactosylceramide (a-GalCer) bound CD1d, another antigen found on the surface of several cancer types.More

No Corporate Spotlight currently available.

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
9.9¢ 		Change
0.001(1.02%) 		Mkt cap ! $116.4M
Open High Low Value Volume
9.9¢ 9.9¢ 9.8¢ $13.71K 138.7K

Buyers (Bids)

No. Vol. Price($)
4 119526 9.8¢
 

Sellers (Offers)

Price($) Vol. No.
10.0¢ 190771 5
View Market Depth
Last trade - 10.52am 01/08/2025 (20 minute delay) ?
Last
10.0¢ 		  Change
0.001 ( 1.01 %)
Open High Low Volume
9.9¢ 10.0¢ 9.9¢ 16475
Last updated 11.28am 01/08/2025 ?
ALA (ASX) Chart

Top Stories

Prospect Resources: Replicating the success of Arcadia with ~1b tonne copper ore target

Executive Director, Ian Goldberg joined The Market Online to discuss their Mumbezhi Project, what could be one of the ASX’s largest copper stories.Join the discussion. See what HotCopper users are saying about Prospect Resources and be part of the conversations that move the marke...
ASX Market Open: Trump tariff deadline looms again – and sets up red Friday | Aug 1 Australian shares will end Week 31 on a dour note, down 70 points in futures, with Trump’s long-heralded tariffs unpause date @ which has been pushed back at the eleventh hour before @ inked in for Friday, Aug. 1 in the U.S.Listen to the HotCopper podcast for in-depth discussions ...
Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign Infini Resources’ newly appointed CEO, Rohan Bone joins The Market Online to discuss strategy moving forward. Join the discussion. See what HotCopper users are saying about Infini Resources and be part of the conversations that move the markets.The material provided in this articl...
Redcastle's 'breakout year' continues with optimistic Queen Alexandra scoping study A study run at Queen Alexandra has left Redcastle Resources (ASX:RC1) bullish on its Golden Circle-based project, with the report suggesting the WA explorer has a @high return project” on its hands @ should gold prices hold steady.Listen to the HotCopper podcast for in-depth...
Market shrugs off Bellevue's 'conservative' FY26 guidance Bellevue Gold (ASX:BGL) has inked its FY26 guidance for the year ahead, and the company’s seen a muted share price reaction, dipping down -0.3% on Friday as the market assesses whether or not it likes what it’s seeing. Listen to the HotCopper podcast for in-depth d...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.